Alnylam Pharmaceuticals, Inc. vs HSBC Holdings plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while HSBC Holdings plc trades at $104.06 (market cap $353.82B). The key difference: HSBC Holdings plc is far larger — about 12× Alnylam Pharmaceuticals, Inc.'s market cap, and HSBC Holdings plc pays a 3.63% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HSBC | |
|---|---|---|
Market Cap | $29.60B | $353.82B |
Sector | Health | Technology |
52-Week High | $491.22 | $107.86 |
52-Week Low | $205.48 | $63.84 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 3.63% |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
HSBC trades at $104.05, up 0.71% today, with a bullish technical signal from moving averages and a P/E of 14.74. The bank reported strong Q2 2026 results, including a 7% revenue increase and a $1 billion buyback, while maintaining a 34.54% net income margin. Recent news highlights leadership changes and China-related market pressures.
Outlook remains positive due to earnings momentum and shareholder returns, but risks include China regulatory shifts and valuation concerns after a 40% run. Analyst consensus is mixed with 38% buy ratings, suggesting cautious optimism amid growth and external headwinds.
Trailing returns across standard periods
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →